[Therapeutic inhibition of Epstein-Barr virus-associated tumor cell growth by dominant-negative EBNA1].
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1), a latent viral protein consistently expressed in infected proliferating cells, is essentially required in trans to maintain EBV episomes in cells. Thus EBNA1 will be an appropriate target for specific molecular therapy against EBV-associated cancers. We constructed a mutant (mt) EBNA1 lacking the N-terminal-half, relative to wild-type (wt) EBNA1, and demonstrated that it exerted dominant-negative effects on maintenance of the viral episome from cells regardless of viral latency or tissue origin thereby leading to significant suppression of naturally EBV-harboring Burkitt's lymphoma cell growth in vitro and in vivo. Our mutant can act as dominant-negative (dn) EBNA1 and will afford an additional therapeutic strategy specifically targeting EBV-associated malignancies. The similar approach can be applicable to exploit novel remedial protocols against uncontrollable diseases caused by other persistently-infected viruses. In addition, dnEBNA1 may also provide a useful analytical tool for the possible oncogenic function(s) of wtEBNA1.
Imai
Shosuke
S
Department of Molecular Microbiology and Infections, Kochi Medical School, Nankoku, Kochi, Japan. shoimai@med.kochi-u.ac.jp
Kuroda
Masayuki
M
Yamashita
Ryusuke
R
Ishiura
Yoshihito
Y
D002051:Burkitt Lymphoma / Q000473:pathology / Q000628:therapy* / Q000821:virology*; D049109:Cell Proliferation; D019309:Epstein-Barr Virus Nuclear Antigens / Q000737:chemistry / Q000235:genetics / Q000502:physiology; D015316:Genetic Therapy; D004854:Herpesvirus 4, Human; D006801:Humans; D009154:Mutation; D010957:Plasmids; D017434:Protein Structure, Tertiary / Q000235:genetics; D014407:Tumor Cells, Cultured
D019309:Epstein-Barr Virus Nuclear Antigens; C417029:EBV-encoded nuclear antigen 1